Related Experiment Video
Updated: Jun 19, 2026

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
Published on: March 15, 2024
Radiotherapeutic treatment of Peyronie s disease
1Erasmus MC-Daniel den Hoed Cancer Center, Department of Radiation Oncology, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands. l.incrocci@erasmusmc.nl
Abstract:
Peyronie's disease is a benign condition, affecting middle-aged men of between 40 and 60 years of age. The symptoms are penile pain in the early inflammatory phase, curvature during erection and erectile dysfunction. The origin of Peyronie's disease is not fully understood. A trauma of the penis with subsequent deposition of fibrin and formation of a fibrotic plaque in the tunica albuginea is the most likely pathophysiological mechanism. Empirical treatments have been attempted with inconclusive results since most of the studies were noncontrolled. In this review, the most important data on the epidemiology, etiology, diagnostic approaches and treatment modalities of Peyronie's disease are addressed. Low-dose (12-15 Gy) radiotherapy has been reported as a successful treatment modality to reduce penile pain and curvature in the early stages of the disease, in noncontrolled studies. Currently, no side effects have been reported. This review critically addresses Peyronie's disease, its treatments, corresponding outcomes and future treatment possibilities. The problems of obtaining good-quality outcomes data for radiotherapeutic approaches are highlighted.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Coronary Artery Disease V: Interprofessional Care

